France's MaaT Pharma 2025 revenue rises 40.7% but misses expectations

Maat Pharma SA

31/03/2026 06:42

Overview

France clinical-stage biotech's 2025 revenue rose 40.7% yr/yr but missed analyst expectations

Net loss widened to €31.1 mln for 2025 from €28.9 mln in 2024

Company submitted EMA marketing authorization application for lead drug MaaT013

Outlook

Company expects EMA feedback on MaaT013 (Xervyteg) mid-2026, with commercial readiness activities ongoing

MaaT Pharma now expects topline results for MaaT033 PHOEBUS trial in Q4 2028, delayed from Q4 2027

Company estimates cash runway to August 2026, including upcoming EIB Tranche B funding

Result Drivers

EAP REVENUE GROWTH - Co said 38% yr/yr increase in EAP revenue reflected growing adoption in hemato-oncology medical community

REGULATORY PREPARATIONS - Higher sales & distribution and regulatory expenses linked to EMA submission for MaaT013

CLINICAL PROGRESS - Increased R&D costs were atrributed to advancement of clinical and operational activities

Company press release: ID:nBw6VbZX3a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Miss
EUR 4.5 mln
EUR 12.97 mln (5 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Maat Pharma SA is €17.00, about 178.7% above its March 30 closing price of €6.10

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)